Although there is controversy about the absolute need for a reversal agent for the new direct
oral anticoagulants (DOACs), the absence of such an agent is a barrier to more widespread …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Highlights•Reversal of novel oral anticoagulants (NOACs) is a challenge.•Prothrombin
complex concentrates are partially effective reversal agents for NOACs.•Idarucizumab is a …

In the last decade, several direct oral anticoagulants (DOAC; dabigatran, rivaroxaban,
apixaban, edoxaban) have been marketed for prophylaxis and/or treatment of …

Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban
form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively …

Direct oral anticoagulants (DOACs) have at least noninferior efficacy compared with other
oral anticoagulants and have ancillary benefits, including overall better safety profiles, lack …

Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor,
and specific inhibitors of activated coagulation factor X (FXa; eg apixaban, betrixaban …

The direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulants
for both stroke prevention in patients with non-valvular atrial fibrillation and the treatment …

Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and
direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were …

The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants
used for the long-term treatment or prevention of venous thromboembolism or stroke in …